SH3PXD2A

Across TCGA pan-cancer cohorts, SH3PXD2A RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of SH3PXD2A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SH3PXD2A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SH3PXD2A is over-expressed in tumor, although a few such as UCEC and BLCA show the opposite, repressed pattern.

KIRC, HNSC, and LIHC are the cancer types where SH3PXD2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SH3PXD2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	+1.125	<.001	11	view →
HNSC	All	All	+0.669	<.001	9	view →
LIHC	Female	II,III,IV	+1.183	<.001	8	view →
UCEC	All	All	−1.435	<.001	6	view →
BLCA	All	All	−0.653	.003	6	view →
LUSC	Male	All	+0.665	<.001	4	view →
LUAD	All	All	+0.395	.001	4	view →
BRCA	Female	II,III,IV	+0.268	.004	4	view →
CHOL	All	All	+1.932	<.001	3	view →
COAD	Female	III,IV	−0.908	.015	3	view →
PRAD	All	All	−0.640	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

SH3PXD2A–KIRC

Open the KIRC breakdown →